Skip to main navigation Skip to search Skip to main content

Treatment of paroxysmal nonkinesigenic dyskinesia

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Paroxysmal nonkinesigenic dyskinesia (PNKD) is a rare movement disorder characterized by intermittent attacks of hyperkinetic involuntary movements without loss of consciousness. It may be classified into primary (genetic or sporadic) or secondary. The attacks usually occur at rest and may be precipitated by alcohol, coffee, cola, tobacco, fatigue, and emotion. Eighty percent of the patients are of autosomal dominant inheritance with a MR-1 gene mutation on chromosome 2q. Management is the avoidance of precipitating factors. Usually, medical treatment is less rewarding. Medications which have shown benefit in some include carbamazepine, benztropine, or clonazepam. Deep Brain Stimulation (ViM, or GPi target) might be considered in severe and medically refractory cases.

Original languageEnglish
Title of host publicationCurrent Clinical Neurology
Pages317-318
Number of pages2
DOIs
StatePublished - 2019

Publication series

NameCurrent Clinical Neurology
ISSN (Print)1559-0585
ISSN (Electronic)2524-4043

Bibliographical note

Publisher Copyright:
© 2019, Springer Nature Switzerland AG.

Keywords

  • Dystonia
  • Mitochondrial dysfunction
  • Myofibrillogenesis regulator 1 gene
  • Paroxysmal nonkinesigenic dyskinesia PNKD
  • Sleep benefit

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Treatment of paroxysmal nonkinesigenic dyskinesia'. Together they form a unique fingerprint.

Cite this